Paola Rogliani to Bronchodilator Agents
This is a "connection" page, showing publications Paola Rogliani has written about Bronchodilator Agents.
Connection Strength
3.556
-
Beclomethasone dipropionate and formoterol fumarate synergistically interact in hyperresponsive medium bronchi and small airways. Respir Res. 2018 04 12; 19(1):65.
Score: 0.483
-
Is ICS-LAMA an alternative option to treat patients with COPD? Lancet Respir Med. 2018 05; 6(5):316-317.
Score: 0.482
-
Comparative effectiveness of indacaterol/glycopyrronium in the treatment of chronic obstructive pulmonary disease. J Comp Eff Res. 2017 Oct; 6(7):627-636.
Score: 0.462
-
Bronchodilators in subjects with asthma-related comorbidities. Respir Med. 2019 05; 151:43-48.
Score: 0.129
-
Inhaled therapies and cardiovascular risk in patients with chronic obstructive pulmonary disease. Expert Opin Pharmacother. 2019 04; 20(6):737-750.
Score: 0.128
-
Triple therapy versus single and dual long-acting bronchodilator therapy in COPD: a systematic review and meta-analysis. Eur Respir J. 2018 12; 52(6).
Score: 0.126
-
Pharmacokinetic considerations concerning the use of bronchodilators in the treatment of chronic obstructive pulmonary disease. Expert Opin Drug Metab Toxicol. 2018 Oct; 14(10):1101-1111.
Score: 0.125
-
The safety of dual bronchodilation on cardiovascular serious adverse events in COPD. Expert Opin Drug Saf. 2018 06; 17(6):589-596.
Score: 0.121
-
Impact of doxofylline in COPD: A pairwise meta-analysis. Pulm Pharmacol Ther. 2018 08; 51:1-9.
Score: 0.121
-
Emerging biological therapies for treating chronic obstructive pulmonary disease: A pairwise and network meta-analysis. Pulm Pharmacol Ther. 2018 06; 50:28-37.
Score: 0.120
-
Combining long-acting bronchodilators with different mechanisms of action: A pharmacological approach to optimize bronchodilation of equine airways. J Vet Pharmacol Ther. 2018 Aug; 41(4):546-554.
Score: 0.120
-
Use of ICS in COPD: From Blockbuster Medicine to Precision Medicine. COPD. 2017 Dec; 14(6):641-647.
Score: 0.117
-
In stable COPD, long-acting muscarinic antagonist plus long-acting beta-agonists resulted in less exacerbations, pneumonia and larger improvement in FEV 1 than long-acting beta-agonists plus inhaled corticosteroids. Evid Based Med. 2017 10; 22(5):183-184.
Score: 0.115
-
Pharmacological characterization of the interaction between tiotropium and olodaterol administered at 5:5 concentration-ratio in equine bronchi. COPD. 2017 Oct; 14(5):526-532.
Score: 0.115
-
Bronchodilator therapy for chronic cough. Pulm Pharmacol Ther. 2017 Dec; 47:88-92.
Score: 0.113
-
Can a better patients' phenotyping predict the efficacy of tiotropium in symptomatic asthma? Allergy Asthma Proc. 2017 05 01; 38(3):19-20.
Score: 0.113
-
Can a better patient phenotyping predict the efficacy of tiotropium in asthmatic adolescents? Expert Opin Pharmacother. 2017 06; 18(8):833-835.
Score: 0.113
-
Pharmacological treatments in asthma-affected horses: A pair-wise and network meta-analysis. Equine Vet J. 2017 Nov; 49(6):710-717.
Score: 0.113
-
Optimizing drug delivery in COPD: The role of inhaler devices. Respir Med. 2017 03; 124:6-14.
Score: 0.111
-
LABA/LAMA combination in COPD: a meta-analysis on the duration of treatment. Eur Respir Rev. 2017 Jan; 26(143).
Score: 0.111
-
Pharmacological treatment and current controversies in COPD. F1000Res. 2019; 8.
Score: 0.033
-
Impact of LABA/LAMA combination on exercise endurance and lung hyperinflation in COPD: A pair-wise and network meta-analysis. Respir Med. 2017 08; 129:189-198.
Score: 0.029
-
Management of Chronic Obstructive Pulmonary Disease in Patients with Cardiovascular Diseases. Drugs. 2017 May; 77(7):721-732.
Score: 0.028
-
Role of muscarinic antagonists in asthma therapy. Expert Rev Respir Med. 2017 03; 11(3):239-253.
Score: 0.028